Use of and common targets in detection in different leukaemias.2C lymphomas and solid tumors Minimal residual disease
1 use of , common targets in detection in different leukaemias, lymphomas , solid tumors
1.1 acute lymphoblastic leukaemia (all)
1.2 acute myeloid leukaemia (aml)
1.3 chronic lymphocytic leukaemia
1.4 chronic myelogenous leukemia
1.5 follicular lymphoma
1.6 mantle cell lymphoma
1.7 multiple myeloma
1.8 solid tumors
1.9 animal species other humans
use of , common targets in detection in different leukaemias, lymphomas , solid tumors
acute lymphoblastic leukaemia (all)
targets: t(9;22) bcr-abl, t(12;21) etv6-runx1 (tel-aml1), patient specific assays immunoglobulin , t cell receptor genes
uses: chromosomal translocation mrd detection used standard clinical practice. patient specific assays gaining acceptance still used in research protocols.
acute myeloid leukaemia (aml)
targets: t(15;17) pml-rara, t(8;21) aml1-runx1t1 (aml-eto), inv(16)
uses: chromosomal translocation mrd detection used standard clinical practice.
chronic lymphocytic leukaemia
targets: cell surface proteins, patient-specific assays immunoglobulin , t cell receptor genes
uses: immunological methods gaining wider use more advanced flow cytometers utilized clinical testing. patient specific assays still used in research protocols.
chronic myelogenous leukemia
target: t(9;22) bcr-abl
uses: mrd detection of t(9;22) considered standard of care patients cml , extremely valuable patients being treated imatinib mesylate (gleevec/glivec).
follicular lymphoma
targets: t(14;18) igh/bcl2, patient specific assays immunoglobulin , t cell receptor genes.
uses: t(14;18) regularly used mrd detection. patient specific assays still used in research protocols.
mantle cell lymphoma
targets: t(11;14) igh/ccnd1 (igh/bcl1), patient-specific assays immunoglobulin , t cell receptor genes
uses: t(11;14) regularly used mrd detection, assay can reliably detect 40–60% of t(11;14) translocations. patient-specific assays still used in research protocols.
multiple myeloma
targets: m-protein levels in blood, patient-specific assays immunoglobulin , t cell receptor genes (high levels of somatic hypermutation prevent assay reliably working).
uses: m-protein level in blood standard of care , used patients multiple myeloma. patient-specific assays still used in research protocols.
solid tumors
research mrd detection of several solid tumors such breast cancer , neuroblastoma has been performed. these assays have been used sample lymph nodes , blood residual or metastatic tumor cells. applicable targets mrd detection have been more difficult determine in solid tumors , use of mrd in solid tumors less advanced use in leukemia , lymphoma.
animal species other humans
leukaemias , lymphomas potentially monitored in non-human animals, however, no known evidence of such veterinary applications exists date.
Comments
Post a Comment